No definition available.
Systemic atrophies primarily affecting the central nervous system
DOID EFO Endpoint Browser PheWeb
G6_NEUATR
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
1504 |
4. Check minimum number of eventsNone |
1504 |
5. Include endpoints |
1694 |
6. Filter based on genotype QC (FinnGen only) |
1649 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 2
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Systemic atrophies primarily affecting the central nervous system
based on the number of shared cases.
Similar with more cases:
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 16815 | 7755 | 8724 |
| Only index persons | 10265 | 4914 | 5351 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.24 | 0.22 | 0.24 |
| Only index persons | 0.19 | 0.18 | 0.20 |
| Median age at first event (years) | |||
| Whole population | 61.80 | 62.97 | 60.68 |
| Only index persons | 60.13 | 60.86 | 59.47 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1649 | 719 | 930 |
| Unadjusted period prevalence (%) | 0.35 | 0.26 | 0.43 |
| Median age at first event (years) | 63.05 | 61.03 | 64.62 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1694
- Matched controls
- 16940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
JDB10
NOMESCO Finland
Percutaneous gastrostomy
31.3
311.1
207
75
R47.1
ICD-10 Finland
Dysarthria and anarthria
34.9
308.5
198
64
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
30.5
307.7
255
98
G12.2
ICD-10 Finland
Motor neuron disease
14263.2
307.7
794
*
N99
ICPC
Neurological disease other
52.9
307.7
319
74
J96.1
ICD-10 Finland
Chronic respiratory failure
16.0
283.1
255
185
N28
ICPC
Limited function/disability (N)
18.9
260.2
213
128
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
+∞
248.2
232
*
N07XX02
ATC
riluzole; oral
+∞
238.3
223
*
R27.0
ICD-10 Finland
Ataxia, unspecified
48.3
199.9
117
26
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.2
193.3
385
762
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
162.1
153
*
R4130
NOMESCO Finland
Speech therapy
10.5
158.7
184
195
G11.2
ICD-10 Finland
Late-onset cerebellar ataxia
+∞
139.5
132
*
M03BX01
ATC
baclofen; systemic
12.3
133.3
136
119
Z51.5
ICD-10 Finland
Palliative care
4.4
127.6
380
1037
TAB00
NOMESCO Finland
Lumbar puncture
6.9
126.8
211
343
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
7.0
126.4
207
331
R13
ICD-10 Finland
Dysphagia
5.0
122.8
304
715
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.9
121.5
237
451
Z31.5
ICD-10 Finland
Genetic counselling
6.8
118.5
199
326
G12.8
ICD-10 Finland
Other spinal muscular atrophies and related syndromes
+∞
107.4
102
*
N29
ICPC
Neurological sympt/complt other
9.5
97.4
119
134
N03AE01
ATC
clonazepam; systemic
5.1
94.5
219
483
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.0
93.0
131
176
B91
ICD-10 Finland
Sequelae of poliomyelitis
31.6
88.8
58
19
TJD20
NOMESCO Finland
Change of gastrostomy tube
29.1
88.0
59
21
G11.8
ICD-10 Finland
Other hereditary ataxias
+∞
84.1
80
*
G72.9
ICD-10 Finland
Myopathy, unspecified
14.0
84.0
78
58
L28
ICPC
Limited function/disability (L)
2.9
82.8
536
2336
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.7
79.5
289
891
R1250
NOMESCO Finland
Evaluation of functional capability
7.0
79.3
125
190
1380A
ICD-9 Finland
Late effects of acute poliomyelitis[SEQUELAE POLIOMYELITIDIS]
+∞
76.6
73
*
G12.1
ICD-10 Finland
Other inherited spinal muscular atrophy
706.3
69.6
68
*
A28
ICPC
Limited function/disability NOS
2.7
69.3
511
2351
SPAT1229
SPAT
Assessment of need for aid
3.5
63.4
242
765
WX725
NOMESCO Finland
Noninvasive ventilation
4.0
61.1
186
503
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.9
60.3
191
531
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
5.7
57.3
111
207
NXL00
NOMESCO Finland
Biopsy of muscle
21.0
56.7
43
21
N18
ICPC
Paralysis/weakness
6.1
55.8
100
173
N02AA01
ATC
morphine; systemic, rectal
6.1
53.6
96
166
R25.3
ICD-10 Finland
Fasciculation
22.2
52.6
39
18
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.4
52.4
210
681
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.3
52.1
223
753
N19
ICPC
Speech disorder
8.0
52.1
72
94
R26.0
ICD-10 Finland
Ataxic gait
22.8
51.9
38
17
R4120
NOMESCO Finland
Occupational therapy
3.6
51.8
188
572
G11.4
ICD-10 Finland
Hereditary spastic paraplegia
+∞
49.2
47
*
XG466
NOMESCO Finland
Sleep oxymetry
4.8
46.2
109
241
G10
ICD-10 Finland
Huntington disease
+∞
46.0
44
*
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
8.3
45.0
60
75
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.6
44.8
318
1404
R1260
NOMESCO Finland
Evaluation of communicative skills
6.2
44.8
78
131
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.2
44.6
124
312
R4190
NOMESCO Finland
Nutritional therapy
4.1
43.2
125
324
D21
ICPC
Swallowing problem
6.5
42.6
71
114
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
8.0
41.0
56
72
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
37.8
365
1836
R5599
NOMESCO Finland
Other rehabilitation service
4.5
36.9
93
217
F80.1
ICD-10 Finland
Expressive language disorder
9.2
36.1
44
49
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.7
34.3
111
311
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
4.7
34.3
80
175
SPAT1231
SPAT
Assessment of adjustments needed in living environment
4.9
33.4
74
155
R5110, ,
SPAT
2.5
30.9
212
912
G31.0
ICD-10 Finland
Circumscribed brain atrophy
9.9
29.5
34
35
34899
ICD-8 Finland
Motor neurone disease, Other and unspecified manifestations
+∞
29.2
28
*
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
28.5
29.0
39
14
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.1
27.8
77
193
XA402
NOMESCO Finland
ENMG
4.5
27.8
69
159
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
24.3
27.0
38
16
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
5.9
26.3
47
81
XG416
NOMESCO Finland
Measurement of maximal airway pressure
+∞
26.1
25
*
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
7.4
25.5
37
51
SPAT1297
SPAT
Other function in accordance with speech therapy nomenclature
10.5
25.4
28
27
R4120, ,
SPAT
5.5
25.0
49
92
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
4.4
24.8
63
148
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
6.3
24.5
41
66
3342A
ICD-9 Finland
Spinocerebellar disease, Primary cerebellar degeneration
+∞
23.0
22
*
Z50.5
ICD-10 Finland
Speech therapy
5.4
22.8
45
85
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.1
22.7
96
319
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.8
21.8
397
2447
04499
ICD-8 Finland
Late effects of actue poliomyelitis
222.8
21.6
22
*
G62.8
ICD-10 Finland
Other specified polyneuropathies
5.8
21.5
39
68
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.5
21.1
145
622
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.5
20.8
133
551
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
2.3
20.7
174
814
N03AX12
ATC
[U] gabapentin; oral
1.9
20.7
301
1726
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
4.8
20.6
47
101
GX2D5
NOMESCO Finland
Sleep oximetry
8.1
20.0
27
34
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.4
20.0
39
73
G35
ICD-10 Finland
Multiple sclerosis
5.7
20.0
37
66
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
19.7
143
628
Z82.0
ICD-10 Finland
Family history of epilepsy and other diseases of the nervous system
26.4
19.1
26
10
XG467
NOMESCO Finland
Nocturnal CO2 monitoring
34.7
18.9
24
7
G12.0
ICD-10 Finland
Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
+∞
18.8
18
*
SPAT1216
SPAT
Assessment of functional ability
1.8
18.3
307
1836
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.3
18.1
150
698
XA800
NOMESCO Finland
Neuropsychological investigation
2.8
18.0
90
329
R26.2
ICD-10 Finland
Difficulty in walking, not elsewhere classified
4.3
17.9
46
109
G11.18
ICD-10 Finland
Early-onset cerebellar ataxia
181.8
17.5
18
*
WPA13
NOMESCO Finland
Palliative consultation
7.8
17.4
24
31
N70
ICPC
Poliomyelitis
42.5
17.3
21
5
Z50.1
ICD-10 Finland
Other physical therapy
2.5
17.2
115
487
XX9TE
NOMESCO Finland
Compementary ultrasound examination
7.2
17.0
25
35
L99
ICPC
Musculoskeletal disease other
3.6
16.9
55
155
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
5.9
16.2
29
50
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
15.5
16.2
26
17
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
21.2
16.0
23
11
JDB01
NOMESCO Finland
Laparoscopic gastrostomy
60.6
15.8
18
*
L19
ICPC
Muscle symptom/complaint NOS
3.2
15.7
61
193
UDQ12
NOMESCO Finland
Flexible laryngoscopy
2.3
15.7
116
514
3352A
ICD-9 Finland
Anterior horn cell disease, Motor neuron disease[SCLEROSIS LATERALIS AMYOTROPHICA]
+∞
15.6
15
*
G57.3
ICD-10 Finland
Lesion of lateral popliteal nerve
4.2
15.6
41
99
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.6
15.2
561
4094
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
5.3
15.2
30
57
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.6
15.1
514
3683
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
15.0
275
1683
T05
ICPC
Feeding problem of adult
5.2
14.9
30
58
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.6
14.8
500
3574
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
4.9
14.8
32
66
N02AA05
ATC
oxycodone; systemic
1.6
14.6
364
2417
G11.00
ICD-10 Finland
Cerebellar dysplasia and aplasia
+∞
14.6
14
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.7
14.6
282
1750
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
4.3
14.6
37
87
G71.08
ICD-10 Finland
Other muscular dystrophy
36.4
14.4
18
5
A98
ICPC
Health maint/preventive medicine
0.6
14.3
1336
14562
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
17.1
14.3
22
13
XW5WT
NOMESCO Finland
Other blood specimen with radiologicl guidance
27.4
14.3
19
7
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
14.6
14.1
23
16
N05BA06
ATC
lorazepam; systemic, sublingual
2.3
13.7
108
491
WX781
NOMESCO Finland
Remote monitoring, noninvasive ventilation
34.3
13.5
17
5
RS314, ,
NOMESCO Finland
26.0
13.4
18
7
G82.1
ICD-10 Finland
Spastic paraplegia
40.4
13.2
16
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
5.5
13.1
25
46
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
11.1
12.5
23
21
G11.02
ICD-10 Finland
Dysequilibrium syndrome
+∞
12.5
12
*
3343A
ICD-9 Finland
Spinocerebellar disease, Other cerebellar ataxia
+∞
12.5
12
*
Z3229
NOMESCO Finland
Other healthcare associate professional
1.9
12.5
156
846
GX1P5
NOMESCO Finland
Nocturnal CO2 monitoring
130.9
12.4
13
*
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
37.8
12.2
15
*
SPAT1234
SPAT
Support of social functional capacity
2.2
12.1
106
504
M54.1
ICD-10 Finland
Radiculopathy
2.5
12.1
75
307
RS340, ,
NOMESCO Finland
26.9
12.0
16
6
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
3.7
12.0
37
101
G31.2
ICD-10 Finland
Degeneration of nervous system due to alcohol
4.9
11.9
26
54
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.7
11.6
37
103
G13.0
ICD-10 Finland
Paraneoplastic neuromyopathy and neuropathy
+∞
11.5
11
*
3351X
ICD-9 Finland
Anterior horn cell disease, Spinal muscular atrophy[ATROPHIA MUSCULORUM SPINALIS NUD]
+∞
11.5
11
*
G11
ICD-10 Finland
Hereditary ataxia
+∞
11.5
11
*
Z02.4
ICD-10 Finland
Examination for driving licence
0.6
11.4
265
3902
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.5
11.2
459
3383
ABC60
NOMESCO Finland
Decompression of cervical spinal cord
4.8
11.2
25
53
N05BA04
ATC
oxazepam; oral
1.5
11.2
413
2981
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
4.4
11.0
27
62
RS222, ,
NOMESCO Finland
4.1
11.0
30
75
SPAT1167
SPAT
Insertion of urinary catheter
2.4
10.9
72
303
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
3.4
10.9
38
113
N06AA09
ATC
amitriptyline; systemic
1.8
10.8
160
915
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.2
10.8
87
400
Z3226
NOMESCO Finland
Physiotherapist
1.6
10.8
296
2000
A06AD11
ATC
lactulose; oral
1.6
10.8
278
1851
WPA42
NOMESCO Finland
Family-centered psychosocial intervention in palliative care
28.2
10.7
14
5
R49.08
ICD-10 Finland
Other specified dysphonia
3.1
10.7
44
145
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
1.8
10.6
177
1049
TNX05
NOMESCO Finland
Simple incision of soft tissue, unspecified region
14.3
10.5
17
12
ABD40
NOMESCO Finland
Implantation of spinal injection device
110.7
10.4
11
*
34898
ICD-8 Finland
Motor neurone disease, Alii definiti
+∞
10.4
10
*
A120_, ,
NOMESCO Finland
+∞
10.4
10
*
3349X
ICD-9 Finland
Spinocerebellar disease, unspecified
+∞
10.4
10
*
A210_, ,
NOMESCO Finland
+∞
10.4
10
*
7812A
ICD-9 Finland
Symptoms involving nervous and musculoskeletal systems, Abnormality of gait
+∞
10.4
10
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
7.8
10.4
23
30
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
8.8
10.3
21
24
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
2.3
10.3
75
331
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
18.9
10.3
15
8
G82.2
ICD-10 Finland
Paraplegia, unspecified
9.6
10.3
20
21
XKD06
NOMESCO Finland
Physiologic investigation of micturition
2.5
10.3
64
263
OAB43, ,
SPAT
0.5
10.2
119
2112
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
3.7
10.2
31
84
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
3.2
10.1
40
129
SPAT1245
SPAT
Provision of support and information to patient’s family members
2.2
9.9
85
402
N81
ICPC
Injury nervous system other
10.7
9.8
18
17
N06AX21
ATC
duloxetine; oral
1.7
9.7
180
1100
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
5.3
9.6
19
36
WPA43
NOMESCO Finland
A doctor's home visit to perform palliative care
15.1
9.5
15
10
R5140
NOMESCO Finland
Monitoring the use of the aid
1.7
9.5
191
1193
Z01.8
ICD-10 Finland
Other specified special examinations
1.5
9.5
354
2551
RP120, ,
NOMESCO Finland
+∞
9.4
9
*
F02.29*G10
ICD-10 Finland
Dementia in Huntington's disease without information on additional symptoms
+∞
9.4
9
*
RK110, ,
NOMESCO Finland
4.4
9.3
23
53
Z46.9
ICD-10 Finland
Fitting and adjustment of unspecified device
3.5
9.2
31
90
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
4.2
9.2
24
58
J96.9
ICD-10 Finland
Respiratory failure, unspecified
4.4
9.1
22
50
M47.1
ICD-10 Finland
Other spondylosis with myelopathy
3.5
9.1
30
86
RS221, ,
NOMESCO Finland
3.5
9.1
31
91
RS142, ,
NOMESCO Finland
18.7
8.9
13
7
AA1AD
NOMESCO Finland
CT of head and brain
1.4
8.9
497
3854
N03AF01
ATC
carbamazepine; oral, rectal
2.0
8.9
91
460
JDB00
NOMESCO Finland
Gastrostomy
24.1
8.9
12
5
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
3.1
8.8
35
113
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.6
8.8
173
2670
G40.9
ICD-10 Finland
Epilepsy, unspecified
2.3
8.7
63
277
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
1.6
8.7
197
1267
N94
ICPC
Peripheral neuritis/neuropathy
14.1
8.7
14
10
M41.4
ICD-10 Finland
Neuromuscular scoliosis
50.2
8.7
10
*
N06AB04
ATC
citalopram; systemic
1.5
8.6
306
2178
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
2.5
8.6
54
223
Z99.8
ICD-10 Finland
Dependence on other enabling machines and devices
16.4
8.6
13
8
R4110
NOMESCO Finland
Physiotherapy
1.4
8.5
439
3352
N05BA01
ATC
diazepam; systemic, rectal
1.6
8.5
206
1347
N04BB01
ATC
amantadine; oral
3.5
8.5
29
85
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
20.1
8.5
12
6
XKC03
NOMESCO Finland
Water cystometry
2.4
8.4
54
225
G04BD12
ATC
mirabegron; oral
1.6
8.4
208
1369
G13.2*E03.9
ICD-10 Finland
Systemic atrophy primarily affecting central nervous system in myxoedema
+∞
8.3
8
*
A220_, ,
NOMESCO Finland
+∞
8.3
8
*
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.1
8.2
81
405
N87
ICPC
Parkinsonism
3.1
8.1
33
108
N06AB10
ATC
escitalopram; oral
1.5
8.1
261
1818
WYA20, ,
SPAT
4.6
8.1
19
42
OAA67, ,
SPAT
0.4
8.1
50
1106
Z93.1
ICD-10 Finland
Gastrostomy status
17.3
8.1
12
7
R33
ICD-10 Finland
Retention of urine
1.7
8.0
160
996
XG410
NOMESCO Finland
Flow-volume spirometry
2.1
8.0
72
347
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
10.1
8.0
15
15
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
2.0
8.0
86
443
WPA40
NOMESCO Finland
Individual-centered psychosocial intervention in palliative care
22.1
8.0
11
5
ZY010
NOMESCO Finland
Hospital outpatient
2.1
8.0
74
361
R42
ICD-10 Finland
Dizziness and giddiness
1.4
8.0
368
2752
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
1.7
8.0
136
812
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
9.4
7.8
15
16
Z2446
NOMESCO Finland
Social worker
1.8
7.7
106
593
N06DX01
ATC
memantine; oral
0.4
7.6
39
929
R1420
NOMESCO Finland
Assessment of rehabilitation needs and/or compilation of rehabilitation plan
11.9
7.6
13
11
R25.1
ICD-10 Finland
Tremor, unspecified
2.3
7.5
53
231
R1410
NOMESCO Finland
Drawing up a rehabilitation plan
6.2
7.5
19
31
TKC20, ,
SPAT
4.3
7.5
19
45
R1420, ,
SPAT
6.5
7.4
18
28
N05BA09
ATC
clobazam; oral
6.5
7.4
18
28
R4130, ,
SPAT
7.7
7.4
16
21
34800
ICD-8 Finland
Motor neurone disease, Amyotrophic lateral sclerosis
+∞
7.3
7
*
SPAT1254
SPAT
Administration of medicine
1.5
7.3
235
1638
TNH33
NOMESCO Finland
Custom moulded brace, ankle or foot
3.2
7.3
28
89
Z73.6
ICD-10 Finland
Limitation of activities due to disability
3.9
7.3
21
55
SPAT1262
SPAT
Handing over of treatment supplies
1.5
7.2
275
1980
S12
ICPC
Insect bite/sting
0.4
7.2
36
867
OAA80, ,
SPAT
0.3
7.1
18
602
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
8.0
7.1
15
19
WPA10, ,
SPAT
8.0
7.1
15
19
TJD10
NOMESCO Finland
Insertion of other tube into stomach or duodenum
12.1
7.1
12
10
C10AA07
ATC
rosuvastatin; oral
0.7
7.0
319
4180
Z2445
NOMESCO Finland
Psychologist
2.2
6.9
55
253
XA421
NOMESCO Finland
Nocturnal polygraphy
7.6
6.9
15
20
K11.72
ICD-10 Finland
Xerostomia
13.8
6.9
11
8
R26
ICD-10 Finland
Abnormalities of gait and mobility
13.8
6.9
11
8
G72.8
ICD-10 Finland
Other specified myopathies
2.7
6.8
36
137
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
8.3
6.8
14
17
N04BC05
ATC
pramipexole; oral
1.7
6.8
121
731
N06AX11
ATC
mirtazapine; oral
1.3
6.8
499
4017
G60.9
ICD-10 Finland
Hereditary and idiopathic neuropathy, unspecified
40.2
6.8
8
*
ZX120, ,
SPAT
3.1
6.7
27
88
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
1.9
6.7
81
435
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
3.9
6.7
19
49
U04
ICPC
Incontinence urine
1.8
6.7
102
591
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
2.0
6.7
73
380
GD1AA, ,
SPAT
0.5
6.6
79
1398
R63.4
ICD-10 Finland
Abnormal weight loss
2.0
6.6
70
360
R99
ICD-10 Finland
Other ill-defined and unspecified causes of mortality
2.2
6.6
50
226
RT274, ,
NOMESCO Finland
12.3
6.6
11
9
RS310, ,
NOMESCO Finland
12.3
6.6
11
9
A29
ICPC
General symptom/complaint other
1.5
6.6
220
1544
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.0
6.6
66
333
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
1.8
6.6
99
571
G81.9
ICD-10 Finland
Hemiplegia, unspecified
3.4
6.6
23
69
GX1D5
NOMESCO Finland
Flow volume spirometry
8.7
6.6
13
15
N02BF01
ATC
gabapentin; oral
1.6
6.5
157
1025
SPAT1125
SPAT
Stoma care and guidance
2.7
6.5
33
123
WX320
NOMESCO Finland
Spinalanesthesy
0.7
6.4
214
2973
N03AX16
ATC
[U] pregabalin
1.4
6.4
340
2595
RP130, ,
NOMESCO Finland
70.1
6.4
7
*
N07XX06
ATC
tetrabenazine; oral
70.1
6.4
7
*
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
1.9
6.4
73
385
V700A
ICD-9 Finland
General medical examination, Routine general medical examination at a health care facility
2.4
6.4
41
172
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
1.7
6.4
110
660
R4110, ,
SPAT
1.5
6.4
204
1419
R69
ICD-10 Finland
Unknown and unspecified causes of morbidity
2.7
6.3
33
125
RS122, ,
NOMESCO Finland
8.2
6.3
13
16
WPA44
NOMESCO Finland
Nursing home for palliative care
8.2
6.3
13
16
N07AA02
ATC
pyridostigmine; systemic
5.5
6.3
17
31
UJC01
NOMESCO Finland
Scopy of lower throat
3.3
6.3
23
71
3350A
ICD-9 Finland
Anterior horn cell disease, Werdnig-Hoffmann disease[MORBUS WERDNIG-HOFFMANN]
+∞
6.3
6
*
A222_, ,
NOMESCO Finland
+∞
6.3
6
*
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
6.3
6
*
3348X
ICD-9 Finland
Spinocerebellar disease, Other spinocerebellar diseases
+∞
6.3
6
*
A211_, ,
NOMESCO Finland
+∞
6.3
6
*
M89.6
ICD-10 Finland
Osteopathy after poliomyelitis
+∞
6.3
6
*
H02AB02
ATC
dexamethasone; systemic
0.5
6.2
64
1185
Z99.1
ICD-10 Finland
Dependence on respirator
26.8
6.2
8
*
G98
ICD-10 Finland
Other disorders of nervous system, not elsewhere classified
26.8
6.2
8
*
WPA43, ,
SPAT
7.0
6.2
14
20
RS230, ,
NOMESCO Finland
5.4
6.2
17
32
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
3.4
6.1
21
62
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
2.8
6.1
29
105
J96.0
ICD-10 Finland
Acute respiratory failure
2.7
6.0
30
111
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Proper column names.
- Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV not working.
- No filters and sorters.
- Limited amount of endpoints with TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
riluzole; oral
N07XX02 (21604842)
N07XX02 (21604842)
Motor neuron disease
G12.2 (45591160)
G12.2 (45591160)
Late effects of acute poliomyelitis[SEQUELAE POLIOMYELITIDIS]
1380A (2000400975)
1380A (2000400975)
Hereditary spastic paraplegia
G11.4 (45533130)
G11.4 (45533130)
Ataxia, unspecified
R27.0 (45539329)
R27.0 (45539329)
Other inherited spinal muscular atrophy
G12.1 (45547727)
G12.1 (45547727)
Huntington disease
G10 (45562075)
G10 (45562075)
Hereditary ataxia, unspecified
G11.9 (45562076)
G11.9 (45562076)
Late-onset cerebellar ataxia
G11.2 (45581480)
G11.2 (45581480)
Other hereditary ataxias
G11.8 (45586276)
G11.8 (45586276)
Other spinal muscular atrophies and related syndromes
G12.8 (45600771)
G12.8 (45600771)
Spinal muscular atrophy, unspecified
G12.9 (45600772)
G12.9 (45600772)
Degenerative disease of nervous system, unspecified
G31.9 (45600776)
G31.9 (45600776)
Speech therapy
R4130 (2001310235)
R4130 (2001310235)
Fasciculation
R25.3 (45568124)
R25.3 (45568124)
Circumscribed brain atrophy
G31.0 (45591166)
G31.0 (45591166)
Spinal muscular atrophy and related syndromes
G12 (45600770)
G12 (45600770)
Anterior horn cell disease, Motor neuron disease[SCLEROSIS LATERALIS AMYOTROPHICA]
3352A (2000403047)
3352A (2000403047)
Extensive MRI examination of brain with high intensity magnet
AA1CG (2001300116)
AA1CG (2001300116)
Biopsy of muscle
NXL00 (2001308515)
NXL00 (2001308515)
Other rehabilitation service
R5599 (2001310270)
R5599 (2001310270)
Limited function/disability (N)
N28 (2002000733)
N28 (2002000733)
Neurological disease other
N99 (2002000796)
N99 (2002000796)
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 (2002330110)
SMOKING-2-2-0 (2002330110)
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 (2002330113)
SMOKING-2-3-0 (2002330113)
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 (2002330116)
SMOKING-1-1-0 (2002330116)
Acetylcholine receptor Ab [Moles/volume] in Serum
20427-1 (3006257)
20427-1 (3006257)
Appearance of Cerebral spinal fluid
10333-3 (3023410)
10333-3 (3023410)
Body height measure
50373000 (4177340)
50373000 (4177340)
Body mass index
60621009 (4245997)
60621009 (4245997)
Ataxic gait
R26.0 (45534437)
R26.0 (45534437)
Dysarthria and anarthria
R47.1 (45558471)
R47.1 (45558471)
Gas panel - Central venous blood
97535-9 (1616796)
97535-9 (1616796)
Motor neurone disease, Other and unspecified manifestations
34899 (2000302257)
34899 (2000302257)
Spinocerebellar disease, Primary cerebellar degeneration
3342A (2000403037)
3342A (2000403037)
Essential hypertension, Unspecified
4019X (2000403546)
4019X (2000403546)
Cerebellar dysplasia and aplasia
G11.00 (2000502111)
G11.00 (2000502111)
Standard MRI examination of brain with high intensity magnet
AA1BG (2001300112)
AA1BG (2001300112)
ENMG
XA402 (2001300405)
XA402 (2001300405)
Lumbar puncture
TAB00 (2001300538)
TAB00 (2001300538)
Thorax X-ray examination outside radiological department
GD1UA (2001303652)
GD1UA (2001303652)
Percutaneous gastrostomy
JDB10 (2001304713)
JDB10 (2001304713)
Cervical spine MRI examination with high intensity magnet
NA1BG (2001306990)
NA1BG (2001306990)
Thoracal spine MRI examination with high intensity magnet
NA2BG (2001307013)
NA2BG (2001307013)
Nutritional guidance related to treatment and rehabilitation for medical condition
OAB74 (2001308652)
OAB74 (2001308652)
Physiotherapy
R4110 (2001310233)
R4110 (2001310233)
Nutritional therapy
R4190 (2001310243)
R4190 (2001310243)
Teaching
WZC30 (2001310891)
WZC30 (2001310891)
Other blood specimen with radiologicl guidance
XW5WT (2001311101)
XW5WT (2001311101)
Physiotherapist
Z3226 (2001311560)
Z3226 (2001311560)
Other healthcare associate professional
Z3229 (2001311561)
Z3229 (2001311561)
Swallowing problem
D21 (2002000320)
D21 (2002000320)
Feeding problem of adult
T05 (2002001069)
T05 (2002001069)
Hemoglobin [Mass/volume] in Arterial blood
30313-1 (3002173)
30313-1 (3002173)
Base excess in Arterial blood by calculation
1925-7 (3003396)
1925-7 (3003396)
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 (3005895)
2639-3 (3005895)
Thiamine [Moles/volume] in Blood
32554-8 (3006653)
32554-8 (3006653)
Neuronal Ab [Presence] in Cerebral spinal fluid
31531-7 (3006804)
31531-7 (3006804)
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 (3007220)
2157-6 (3007220)
Bicarbonate [Moles/volume] in Arterial blood
1960-4 (3008152)
1960-4 (3008152)
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 (3008230)
7818-8 (3008230)
pH of Capillary blood
2745-8 (3009343)
2745-8 (3009343)
Angiotensin converting enzyme [Enzymatic activity/volume] in Cerebral spinal fluid
12480-0 (3009991)
12480-0 (3009991)
Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
22126-7 (3010380)
22126-7 (3010380)
Fractional oxyhemoglobin in Arterial blood
2714-4 (3014007)
2714-4 (3014007)
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 (3014218)
19230-2 (3014218)
Chloride [Moles/volume] in Serum or Plasma
2075-0 (3014576)
2075-0 (3014576)
Bicarbonate [Moles/volume] in Capillary blood
1961-2 (3015235)
1961-2 (3015235)
Differential panel - Cerebral spinal fluid
29584-0 (3016018)
29584-0 (3016018)
Oxygen saturation in Arterial blood
2708-6 (3016502)
2708-6 (3016502)
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 (3016888)
7817-0 (3016888)
Oxygen content in Arterial blood
19218-7 (3017569)
19218-7 (3017569)
Gas panel - Arterial blood
24336-0 (3019060)
24336-0 (3019060)
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 (3019902)
13317-3 (3019902)
pH of Arterial blood
2744-1 (3019977)
2744-1 (3019977)
Body temperature
8310-5 (3020891)
8310-5 (3020891)
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 (3023024)
2020-6 (3023024)
Oxygen [Partial pressure] in Arterial blood
2703-7 (3027801)
2703-7 (3027801)
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 (3027946)
2019-8 (3027946)
Aldolase [Enzymatic activity/volume] in Serum or Plasma
1761-6 (3027953)
1761-6 (3027953)
Oxygen [Partial pressure] in Capillary blood
2704-5 (3028626)
2704-5 (3028626)
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 (3028653)
2030-5 (3028653)
Clinical Cytogenetics and Genomics
OMOP4822000 (32411)
OMOP4822000 (32411)
Cerebrospinal fluid IgG ratio and IgG index
1324000 (4027681)
1324000 (4027681)
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 (43055554)
72720-6 (43055554)
Malaise and fatigue
R53 (45553741)
R53 (45553741)
Dyspnoea
R06.0 (45558449)
R06.0 (45558449)
Polyneuropathy, unspecified
G62.9 (45566898)
G62.9 (45566898)
Myopathy, unspecified
G72.9 (45571825)
G72.9 (45571825)
Dysphagia
R13 (45573013)
R13 (45573013)
Genetic counselling
Z31.5 (45590715)
Z31.5 (45590715)
Expressive language disorder
F80.1 (45595921)
F80.1 (45595921)
Other and unspecified abnormalities of gait and mobility
R26.8 (45597174)
R26.8 (45597174)
Pneumonia, unspecified
J18.9 (45601123)
J18.9 (45601123)
Muscle wasting and atrophy, not elsewhere classified
M62.5 (45606275)
M62.5 (45606275)
Observation for suspected nervous system disorder
Z03.3 (45609903)
Z03.3 (45609903)
pregabalin; oral
N02BF02 (955152)
N02BF02 (955152)
Neurology
13 (38004458)
13 (38004458)
Chronic respiratory failure
J96.1 (45557632)
J96.1 (45557632)
Inpatient Hospital
21 (8717)
21 (8717)
baclofen; oral, parenteral
M03BX01 (21604115)
M03BX01 (21604115)
Supplier / Service Provider
OMOP5117446 (33004)
OMOP5117446 (33004)
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 (3015322)
2865-4 (3015322)
Palliative care
Z51.5 (45547323)
Z51.5 (45547323)
Protein electrophoresis panel - Serum or Plasma
24351-9 (3004588)
24351-9 (3004588)
Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
35559-4 (3035797)
35559-4 (3035797)
Physical Medicine And Rehabilitation
25 (38004468)
25 (38004468)
Care involving use of other rehabilitation procedures
Z50.8 (45556842)
Z50.8 (45556842)
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 (3043723)
32730-4 (3043723)
Conditions requiring daily forced enteral nutrition
504 (2001600363)
504 (2001600363)
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 (3043747)
32731-2 (3043747)
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 (3005229)
2868-8 (3005229)
Spinal stenosis
M48.0 (45557888)
M48.0 (45557888)
General Practice
1 (38004446)
1 (38004446)
Anesthesiology Critical Care Medicine
OMOP4821991 (45756751)
OMOP4821991 (45756751)
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 (3023465)
2874-6 (3023465)
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 (45587505)
R29.8 (45587505)
Limited function/disability (L)
L28 (2002000647)
L28 (2002000647)
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 (3029338)
50796-2 (3029338)
Alpha tocopherol [Moles/volume] in Serum or Plasma
14590-4 (3000208)
14590-4 (3000208)
Pulmonary Disease
29 (38004472)
29 (38004472)
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 (3029713)
51435-6 (3029713)
Protein [Mass/volume] in Serum or Plasma
2885-2 (3020630)
2885-2 (3020630)
Outpatient Visit
OP (9202)
OP (9202)
Neurological sympt/complt other
N29 (2002000734)
N29 (2002000734)
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 (3034780)
2742-5 (3034780)
Occupational therapy
R4120 (2001310234)
R4120 (2001310234)
Aid fitting and borrowing and monitoring of use
SPAT1230 (2001700331)
SPAT1230 (2001700331)
Office Visit
OMOP4822458 (581477)
OMOP4822458 (581477)
Limited function/disability NOS
A28 (2002000162)
A28 (2002000162)
clonazepam; oral, parenteral
N03AE01 (21604415)
N03AE01 (21604415)
Psychiatry
26 (38004469)
26 (38004469)
Internal Medicine
11 (38004456)
11 (38004456)
General psychiatric examination, not elsewhere classified
Z00.4 (45605094)
Z00.4 (45605094)
Home Visit
OMOP4822459 (581476)
OMOP4822459 (581476)
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 (3019473)
2880-3 (3019473)
Emergency Medicine
93 (38004510)
93 (38004510)
Nuclear Ab [Titer] in Serum
29953-7 (3037522)
29953-7 (3037522)
Assessment of adjustments needed in living environment
SPAT1231 (2001700332)
SPAT1231 (2001700332)
Functional capacity evaluation
443351003 (40481051)
443351003 (40481051)
Fitting and adjustment of other specified devices
Z46.8 (45581035)
Z46.8 (45581035)
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 (3016543)
26465-5 (3016543)
Cell count panel - Cerebral spinal fluid
34563-7 (3044290)
34563-7 (3044290)
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 (3027475)
26454-9 (3027475)
Speech disorder
N19 (2002000730)
N19 (2002000730)
FEV1/FVC
19926-5 (3011505)
19926-5 (3011505)
Forced vital capacity [Volume] Respiratory system
19870-5 (3020158)
19870-5 (3020158)
FEV1
20150-9 (3024653)
20150-9 (3024653)
Noninvasive ventilation
WX725 (2001310828)
WX725 (2001310828)
Paediatric neurology
421 (44777781)
421 (44777781)
Treponema pallidum Ab [Presence] in Serum
22587-0 (3019832)
22587-0 (3019832)
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 (3016293)
1963-8 (3016293)
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 (2001310246)
R5110 (2001310246)
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 (3020044)
14744-7 (3020044)
Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 (3029379)
50797-0 (3029379)
Supine thorax X-ray examination
GD1QA (2001303648)
GD1QA (2001303648)
Paralysis/weakness
N18 (2002000729)
N18 (2002000729)
Other specified special examinations
Z01.8 (45581003)
Z01.8 (45581003)
Voluntary or Charitable Agency
251V00000X (38004202)
251V00000X (38004202)
Radiculopathy
M54.1 (45577287)
M54.1 (45577287)
Overnight pulse oximetry
252568001 (4091874)
252568001 (4091874)
Implementation of physical therapy rehabilitation plan
SPAT1223 (2001700324)
SPAT1223 (2001700324)
Nursing episode
950 (44777714)
950 (44777714)
Inpatient Visit
IP (9201)
IP (9201)
HIV 1 and 2 tests - Meaningful Use set
75622-1 (46235355)
75622-1 (46235355)
Folate [Moles/volume] in Red Blood Cells
14731-4 (3019309)
14731-4 (3019309)
Care involving use of rehabilitation procedure, unspecified
Z50.9 (45595525)
Z50.9 (45595525)
Gas panel - Capillary blood
24337-8 (3022313)
24337-8 (3022313)
Essential (primary) hypertension
I10 (45591453)
I10 (45591453)
Functional X-ray examination of swallowing
JC2KB (2001304595)
JC2KB (2001304595)
Fall on same level from slipping, tripping and stumbling
W01 (45756243)
W01 (45756243)
Orthopedic Surgery
20 (38004465)
20 (38004465)
IgG [Mass/volume] in Serum or Plasma
2465-3 (3005719)
2465-3 (3005719)
Monocytes [#/volume] in Blood
26484-6 (3001604)
26484-6 (3001604)
Sleep apnoea
G47.3 (45562094)
G47.3 (45562094)
Bacteria [#/volume] in Urine by Automated count
51480-2 (3031040)
51480-2 (3031040)
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 (3013707)
4537-7 (3013707)
Magnesium [Moles/volume] in Serum or Plasma
2601-3 (3012095)
2601-3 (3012095)
Dizziness and giddiness
R42 (45568132)
R42 (45568132)
Assessment of need for medical rehabilitation
SPAT1215 (2001700316)
SPAT1215 (2001700316)
amitriptyline; oral, parenteral
N06AA09 (21604696)
N06AA09 (21604696)
IgG [Mass/volume] in Cerebral spinal fluid
2464-6 (3007368)
2464-6 (3007368)
Folate [Moles/volume] in Serum or Plasma
14732-2 (3021960)
14732-2 (3021960)
Basophils [#/volume] in Blood
26444-0 (3006315)
26444-0 (3006315)
Eosinophils [#/volume] in Blood
26449-9 (3013115)
26449-9 (3013115)
Other spondylosis with radiculopathy
M47.2 (45591850)
M47.2 (45591850)
Assessment of need for services (elderly/care support)
SPAT1217 (2001700318)
SPAT1217 (2001700318)
Neurosurgery
14 (38004459)
14 (38004459)
oxazepam; oral
N05BA04 (21604569)
N05BA04 (21604569)
Implementation of occupational therapy rehabilitation plan
SPAT1226 (2001700327)
SPAT1226 (2001700327)
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 (3009035)
14685-2 (3009035)
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 (3004490)
19231-0 (3004490)
gabapentin; oral
N02BF01 (955005)
N02BF01 (955005)
Eosinophils/Leukocytes in Blood
26450-7 (3006504)
26450-7 (3006504)
lorazepam; oral, parenteral, sublingual
N05BA06 (21604571)
N05BA06 (21604571)
Lymphocytes [#/volume] in Blood
26474-7 (3019198)
26474-7 (3019198)
Basophils/Leukocytes in Blood
30180-4 (3022096)
30180-4 (3022096)
Monocytes/Leukocytes in Blood
26485-3 (3019069)
26485-3 (3019069)
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 (3026910)
2324-2 (3026910)
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 (40762366)
59275-8 (40762366)
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (3020460)
1988-5 (3020460)
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 (2001304788)
UJD10 (2001304788)
Flexible laryngoscopy
UDQ12 (2001301827)
UDQ12 (2001301827)
Other physical therapy
Z50.1 (45600331)
Z50.1 (45600331)
Neutrophils/Leukocytes in Blood
26511-6 (3018010)
26511-6 (3018010)
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 (3006140)
14631-6 (3006140)
Audiology
64 (38004489)
64 (38004489)
Differential panel, method unspecified - Blood
69738-3 (42870588)
69738-3 (42870588)
Lymphocytes/Leukocytes in Blood
26478-8 (3002030)
26478-8 (3002030)
Support of social functional capacity
SPAT1234 (2001700335)
SPAT1234 (2001700335)
Outpatient Hospital
22 (8756)
22 (8756)
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 (43054903)
72160-5 (43054903)
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 (3021614)
11572-5 (3021614)
Sodium [Moles/volume] in Serum or Plasma
2951-2 (3019550)
2951-2 (3019550)
Potassium [Moles/volume] in Serum or Plasma
2823-3 (3023103)
2823-3 (3023103)
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 (3043924)
40987-0 (3043924)
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 (36031861)
95941-1 (36031861)
Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid
22133-3 (3014973)
22133-3 (3014973)
Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
22118-4 (3011166)
22118-4 (3011166)
CXCL13 Ag [Mass/volume] in Cerebral spinal fluid
74917-6 (44816808)
74917-6 (44816808)
Albumin [Mass/volume] in Serum or Plasma
1751-7 (3024561)
1751-7 (3024561)
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 (3009201)
3016-3 (3009201)
Base excess in Blood by calculation
11555-0 (3012501)
11555-0 (3012501)
Carbon dioxide [Partial pressure] in Blood
11557-6 (3013290)
11557-6 (3013290)
Assessment of need for aid
SPAT1229 (2001700330)
SPAT1229 (2001700330)
INR in Blood by Coagulation assay
34714-6 (3032080)
34714-6 (3032080)
Oxygen [Partial pressure] in Blood
11556-8 (3027315)
11556-8 (3027315)
Taking care of patient’s/customer’s hygiene
SPAT1137 (2001700238)
SPAT1137 (2001700238)
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 (3019050)
31017-7 (3019050)
morphine; oral, parenteral, rectal
N02AA01 (21604256)
N02AA01 (21604256)
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 (3044938)
34487-9 (3044938)
Emergency Room and Inpatient Visit
ERIP (262)
ERIP (262)
Creatinine [Moles/volume] in Serum or Plasma
14682-9 (3020564)
14682-9 (3020564)
Counselling/guidance promoting independent living
SPAT1222 (2001700323)
SPAT1222 (2001700323)
diazepam; oral, parenteral, rectal
N05BA01 (21604566)
N05BA01 (21604566)
CBC panel - Blood by Automated count
58410-2 (40761511)
58410-2 (40761511)
Oxygen saturation in Capillary blood
2709-4 (3021901)
2709-4 (3021901)
In Home Supportive Care Agency
253Z00000X (38004206)
253Z00000X (38004206)
Laboratory Visit
OMOP4822461 (32036)
OMOP4822461 (32036)
Case Management Agency
251B00000X (38004193)
251B00000X (38004193)
Type 2 diabetes mellitus, without complications
E11.9 (45561952)
E11.9 (45561952)
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 (3009542)
20570-8 (3009542)
Hemoglobin [Mass/volume] in Blood
718-7 (3000963)
718-7 (3000963)
Platelets [#/volume] in Blood
26515-7 (3007461)
26515-7 (3007461)
MCV [Entitic mean volume] in Red Blood Cells
30428-7 (3024731)
30428-7 (3024731)
MCH [Entitic mass]
28539-5 (3035941)
28539-5 (3035941)
Erythrocytes [#/volume] in Blood
26453-1 (3026361)
26453-1 (3026361)
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 (2001700321)
SPAT1220 (2001700321)
Leukocytes [#/volume] in Blood
26464-8 (3010813)
26464-8 (3010813)
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 (3016431)
19072-8 (3016431)
Emergency Room Visit
ER (9203)
ER (9203)
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 (40764999)
62238-1 (40764999)
Dietary counselling and surveillance
Z71.3 (45552101)
Z71.3 (45552101)
Monitoring the use of the aid
R5140 (2001310249)
R5140 (2001310249)
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 (3002385)
30385-9 (3002385)
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 (3021347)
1995-0 (3021347)
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 (3003338)
28540-3 (3003338)
Thorax X-ray examination
GD1AA (2001303617)
GD1AA (2001303617)
Normoblasts [#/volume] in Blood
715-3 (3021589)
715-3 (3021589)
Other specified counselling
Z71.8 (45581061)
Z71.8 (45581061)
Medical Oncology
90 (38004507)
90 (38004507)
Counselling and guidance which enhance independent living
R2130 (2001310196)
R2130 (2001310196)
Telehealth
OMOP5556618 (722455)
OMOP5556618 (722455)
buprenorphine; parenteral, sublingual, transdermal
N02AE01 (21604287)
N02AE01 (21604287)
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 (3006923)
1742-6 (3006923)
Abnormal weight loss
R63.4 (45568144)
R63.4 (45568144)
pH of Blood
11558-4 (3010421)
11558-4 (3010421)
duloxetine; oral
N06AX21 (21604749)
N06AX21 (21604749)
escitalopram; oral
N06AB10 (21604718)
N06AB10 (21604718)
Lactate [Moles/volume] in Blood
32693-4 (3047181)
32693-4 (3047181)
Glucose [Moles/volume] in Serum or Plasma
14749-6 (3013826)
14749-6 (3013826)
pH of Serum or Plasma
2753-2 (3018418)
2753-2 (3018418)
IgA [Mass/volume] in Serum or Plasma
2458-8 (3007164)
2458-8 (3007164)
citalopram; oral, parenteral
N06AB04 (21604712)
N06AB04 (21604712)
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 (3035995)
6768-6 (3035995)
Administration of medicine
SPAT1254 (2001700355)
SPAT1254 (2001700355)
tizanidine; oral
M03BX02 (21604116)
M03BX02 (21604116)
Lumbar spine MRI examination with high intensity magnet
NA3BG (2001307034)
NA3BG (2001307034)
Prothrombin time (PT) actual/Normal
5894-1 (3033658)
5894-1 (3033658)
oxybutynin; oral, transdermal
G04BD04 (21602637)
G04BD04 (21602637)
Calcium [Moles/volume] in Serum or Plasma
2000-8 (3015377)
2000-8 (3015377)
Otolaryngology
4 (38004449)
4 (38004449)
Bacteria identified in Urine by Culture
630-4 (3026008)
630-4 (3026008)
lactulose; oral
A06AD11 (21600571)
A06AD11 (21600571)
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 (3051714)
48065-7 (3051714)
propranolol; oral, parenteral
C07AA05 (21601670)
C07AA05 (21601670)
Gastroenterology
10 (38004455)
10 (38004455)
CBC W Ordered Manual Differential panel - Blood
57782-5 (40760892)
57782-5 (40760892)
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 (3013721)
1920-8 (3013721)
oxycodone; oral, parenteral
N02AA05 (21604260)
N02AA05 (21604260)
Treatment plan or consultation
WZC00 (2001310885)
WZC00 (2001310885)
Speech therapy
Z50.5 (45547321)
Z50.5 (45547321)
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 (3019800)
6598-7 (3019800)
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 (3008486)
14920-3 (3008486)
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 (40771025)
68438-1 (40771025)
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 (4010399)
113016006 (4010399)
Upper gastrointestinal surgery
106 (44777669)
106 (44777669)
Hand/finger symptom/complaint
L12 (2002000636)
L12 (2002000636)
Tissue transglutaminase IgG Ab [Units/volume] in Serum
32998-7 (3046870)
32998-7 (3046870)
Pharmacy visit
OMOP4822462 (581458)
OMOP4822462 (581458)
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 (3023602)
14646-4 (3023602)
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 (3004410)
4548-4 (3004410)
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 (3019900)
14647-2 (3019900)
Counselling and guidance related to nutrition and weight management
SPAT1306 (2001700407)
SPAT1306 (2001700407)
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 (3001308)
22748-8 (3001308)
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
118
82
15.39
132.48
1.1
1.0
—
—
—
0
0
117
88
14.21
125.59
1.1
1.1
37.19
42.51
mg/l
0.43
99
74
115
85
14.44
124.68
1.1
1.1
270.11
292.82
mg/l
0.37
103
73
209
371
6.29
114.91
1.5
1.4
556.36
579.62
mg/l
0.09
202
348
126
126
10.72
112.70
1.0
1.1
—
—
—
0
0
109
97
11.94
105.38
1.1
1.1
0.09
4.93
nmol/l
1.54
13
17
183
330
6.10
98.64
1.5
1.4
3.76
3.79
mmol/l
0.08
172
310
317
915
4.03
96.92
2.6
2.5
17.93
19.50
au/ml
0.13
19
74
295
824
4.12
94.25
1.4
1.3
49.67
57.68
au/ml
0.22
11
64
87
67
13.63
91.84
1.2
1.1
0.51
0.51
ratio
0.03
53
41
173
317
5.96
91.57
1.6
1.6
531.45
836.65
e6/l
0.25
137
249
172
314
5.98
91.39
1.6
1.5
6.19
58.69
e6/l
1.27
128
239
865
4896
2.57
78.04
2.7
2.2
248.90
225.52
u/l
0.36
831
4630
79
70
11.79
76.37
1.1
1.1
1.06
1.09
u/l
0.19
35
36
70
69
10.54
62.91
1.1
1.5
5.49
8.40
u/l
0.60
59
55
288
1203
2.68
45.48
5.1
4.6
5.60
5.15
kpa
11.69
283
1155
328
1472
2.52
44.64
2.3
3.0
67.74
66.35
g/l
3.36
308
1350
254
1038
2.70
41.68
4.7
4.6
3.01
1.89
mmol/l
4.79
227
778
186
709
2.82
34.64
1.6
2.6
3.48
3.67
g/l
1.05
174
648
186
710
2.82
34.54
1.6
2.6
6.97
7.36
g/l
2.78
175
648
186
710
2.82
34.54
1.6
2.6
4.24
4.17
g/l
0.60
175
648
178
664
2.88
34.50
1.6
2.6
2.50
2.95
g/l
8.97
167
602
43
58
7.58
30.20
1.4
1.3
134.74
110.24
nmol/l
0.32
31
40
157
624
2.67
26.81
1.4
2.7
9.89
10.63
g/l
1.23
144
558
1189
13760
0.54
26.67
5.2
6.1
2.71
2.61
mmol/l
3.39
1064
12700
1151
13428
0.55
26.17
4.7
5.2
1.46
1.43
mmol/l
1.33
1039
12359
1162
13516
0.55
26.04
4.7
5.3
4.61
4.51
mmol/l
2.87
1046
12539
378
5940
0.53
25.26
2.0
2.0
1.38
1.34
mmol/l
0.29
321
4934
152
616
2.61
24.93
1.7
2.1
763.92
521.71
ug/l
0.19
144
584
1131
13158
0.58
23.23
6.6
6.9
39.61
39.88
mmol/mol
0.42
1035
12222
340
1999
1.88
21.77
5.8
7.8
5.68
5.11
kpa
8.70
327
1928
339
2000
1.87
21.44
5.7
7.8
11.08
11.91
kpa
3.21
324
1931
1114
12882
0.61
19.87
4.1
4.5
1.30
1.29
mmol/l
0.14
999
11742
332
1990
1.83
19.81
5.8
7.7
3.07
0.91
mmol/l
16.48
284
1638
1175
13393
0.60
19.38
5.0
5.4
5.96
6.04
mmol/l
1.26
1067
12182
138
623
2.32
17.85
1.6
2.7
0.64
1.35
g/l
1.30
124
535
122
525
2.43
17.57
1.5
2.5
0.00
0.01
g/l
0.76
113
472
217
1189
1.95
16.93
2.3
3.2
10.81
10.76
g/l
0.05
194
1104
33
62
5.41
16.87
1.1
1.0
14.82
247.99
ng/l
—
6
17
137
635
2.26
16.65
1.7
2.0
38.11
38.89
u/l
0.20
124
554
881
7016
1.53
16.29
4.6
5.4
35.82
35.15
g/l
3.05
831
6579
196
1056
1.97
16.03
5.9
7.3
26.65
24.51
mmol/l
7.14
188
1014
110
479
2.39
15.44
1.5
2.6
0.00
0.00
g/l
-0.00
102
450
52
159
3.34
14.15
1.1
1.9
—
2306.67
—
0
6
112
514
2.26
13.94
1.5
2.6
0.00
0.00
g/l
-0.00
102
451
25
44
5.75
13.69
1.1
1.1
—
—
—
0
0
25
44
5.75
13.69
1.1
1.1
—
—
—
0
0
134
669
2.09
13.50
5.2
5.1
25.83
24.91
mmol/l
3.26
128
627
281
1791
1.68
13.09
6.1
8.1
94.41
95.28
%
1.08
272
1742
1377
14853
0.61
13.02
29.5
27.5
6.89
6.82
e9/l
0.34
1338
14477
1378
14852
0.61
12.77
29.8
27.6
133.50
134.49
g/l
1.73
1363
14667
1378
14850
0.61
12.72
29.5
27.4
4.42
4.46
e12/l
2.00
1339
14477
1378
14850
0.61
12.72
30.2
28.0
39.79
40.13
%
1.42
1362
14655
1378
14847
0.61
12.64
29.4
27.4
91.42
91.42
fl
0.01
1361
14662
1378
14846
0.62
12.61
29.5
27.4
250.68
244.12
e9/l
3.37
1346
14529
1188
13205
0.66
12.51
19.3
17.7
86.38
77.21
ml/min/173m2
31.69
1085
12320
17
8
21.45
12.01
1.1
1.0
—
—
—
0
0
24
29
8.38
11.30
1.0
1.4
—
—
—
0
0
399
2884
1.50
10.66
1.9
2.0
—
—
—
0
0
1341
14441
0.66
10.38
13.0
12.9
27.34
26.21
u/l
1.23
1299
14012
938
7962
1.40
10.24
7.6
7.8
1.22
1.21
mmol/l
3.75
818
6866
406
5352
0.68
9.95
4.6
4.2
13.92
8.54
mg/mmol
0.81
261
3411
22
47
4.73
9.78
1.1
1.1
—
—
—
0
0
1367
14631
0.66
9.67
25.5
23.8
71.57
81.54
umol/l
14.49
1351
14441
378
2752
1.48
9.63
3.0
3.6
0.82
0.82
mmol/l
0.06
356
2599
419
5451
0.69
9.42
4.3
3.5
7.23
7.56
mmol/l
0.87
350
4602
388
2863
1.46
9.18
1.7
1.8
1124.16
1155.86
nmol/l
0.28
313
2162
84
408
2.11
9.14
2.8
2.2
137.94
128.92
g/l
2.97
72
328
20
42
4.81
9.07
1.2
1.1
—
—
—
0
0
26
69
3.81
8.80
1.3
1.2
—
—
—
0
0
255
3575
0.66
8.29
2.8
3.4
0.79
0.78
ug/l
0.08
182
2418
19
46
4.17
7.28
1.2
1.1
—
—
—
0
0
24
69
3.51
7.27
1.1
1.2
—
—
—
0
0
32
114
2.84
6.86
1.1
1.0
87.86
43.48
ng/l
0.33
23
67
421
3303
1.37
6.75
1.6
1.8
54496372.08
27033395.98
pmol/l
0.31
367
2730
297
2198
1.43
6.73
1.8
1.9
—
—
—
0
0
35
826
0.41
6.68
1.8
1.8
3.46
3.46
mmol/l
0.00
28
613
218
1533
1.48
6.45
6.4
7.5
1.18
1.39
mmol/l
3.83
207
1501
93
531
1.80
6.39
1.3
1.2
7.33
0.99
u/ml
—
6
34
38
155
2.48
6.29
1.2
1.3
—
—
—
0
0
31
114
2.75
6.29
1.1
1.0
292.00
307.70
ng/l
0.12
23
70
21
61
3.47
6.29
1.0
1.0
—
—
—
0
0
823
7167
1.29
6.13
7.4
7.1
1.21
1.21
mmol/l
1.69
759
6622
561
4661
1.30
5.94
1.7
1.8
20.63
20.02
nmol/l
0.45
493
3935
1030
11284
0.78
5.77
23.7
22.6
13.73
13.76
%
0.33
1022
11121
30
114
2.66
5.75
1.1
1.0
875.00
614.91
ng/l
2.40
17
69
391
4834
0.75
5.66
4.6
4.7
21.11
21.78
%
0.47
206
2452
1351
14265
0.74
5.61
24.1
22.0
3.95
4.00
mmol/l
8.96
1326
13967
1350
14245
0.74
5.45
24.1
21.8
139.61
139.65
mmol/l
0.23
1331
13969
218
1594
1.42
5.25
2.3
2.4
0.21
0.21
g/l
0.60
209
1478
795
6980
1.26
5.23
2.2
2.2
93.47
94.82
pmol/l
0.33
449
3755
10
12
8.37
5.06
1.1
1.0
—
—
—
0
0
1030
11204
0.79
4.93
25.7
23.8
331.79
332.16
g/l
0.61
1019
11130
67
1134
0.57
4.82
1.9
2.1
3.50
3.51
ratio
0.03
60
925
270
2077
1.36
4.79
1.9
1.9
—
—
—
0
0
15
42
3.59
4.77
1.1
1.1
—
—
—
0
0
44
219
2.04
4.64
1.0
1.1
18.65
78.43
iu/ml
0.75
17
35
150
1047
1.47
4.63
6.7
9.2
25.87
24.21
mmol/l
6.52
144
1026
11
19
5.82
4.44
1.1
1.1
—
—
—
0
0
10
16
6.28
4.29
1.1
1.1
—
—
—
0
0
10
16
6.28
4.29
1.1
1.3
—
—
—
0
0
11
20
5.53
4.29
1.1
1.1
—
—
—
0
0
11
20
5.53
4.29
1.1
1.1
—
—
—
0
0
836
7487
1.23
4.28
15.0
17.6
1.27
1.31
inr
1.14
695
6282
516
5995
0.80
4.25
5.0
5.8
8.48
3.66
ug/l
0.88
455
5393
18
62
2.92
4.17
2.4
1.7
42.12
39.55
g/l
1.17
18
62
227
1742
1.35
4.08
4.8
4.2
3.21
1.85
mmol/l
5.55
209
1474
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
22
89
2.49
3.80
1.1
1.1
—
—
—
0
0
23
96
2.42
3.73
1.5
1.4
—
—
—
0
0
23
96
2.42
3.73
1.5
1.4
—
—
—
0
0
51
293
1.76
3.56
1.2
1.2
38.23
53.39
u/ml
—
6
33
230
1805
1.32
3.56
4.7
4.2
6.20
5.82
kpa
4.31
224
1751
8
13
6.18
3.50
1.4
2.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
21
87
2.43
3.47
1.1
1.1
—
—
—
0
0
64
396
1.64
3.43
2.8
3.1
31.31
36.61
umol/l
0.84
58
348
13
347
0.37
3.43
1.0
1.2
1.42
1.54
g/l
0.91
13
347
23
101
2.29
3.36
2.5
2.2
—
—
—
0
0
141
1039
1.39
3.29
4.8
4.6
25.66
24.14
mmol/l
5.98
141
1024
1317
13761
0.81
3.25
21.0
18.2
26.46
26.31
mg/l
0.05
1156
11515
343
4060
0.81
3.18
3.1
3.0
348.02
354.19
umol/l
0.46
302
3552
194
1516
1.32
3.11
4.4
3.7
4.56
4.52
kpa
0.10
188
1469
85
578
1.50
3.07
2.0
1.8
9.16
7.45
iu/ml
0.23
17
133
61
387
1.60
3.00
1.3
1.2
2.63
2.47
u/ml
—
8
34
61
388
1.59
2.97
1.3
1.2
1.88
7.75
u/ml
—
9
56
146
1103
1.35
2.95
1.7
1.7
—
—
—
0
0
83
567
1.49
2.94
1.9
1.8
—
—
—
0
0
130
967
1.37
2.90
9.2
10.6
17.12
15.87
%
6.80
124
936
7
13
5.40
2.87
1.0
1.1
—
—
—
0
0
89
623
1.45
2.80
1.9
2.0
—
—
—
0
0
80
552
1.47
2.72
1.4
1.3
—
—
—
0
0
969
9018
1.17
2.71
5.8
5.5
6.65
6.79
mmol/l
1.45
929
8626
362
3095
1.22
2.71
1.4
1.3
1.37
1.64
u/ml
0.18
93
810
188
2341
0.78
2.69
1.3
1.3
4.34
12.56
u/ml
3.26
74
851
16
68
2.37
2.56
1.6
1.4
—
—
—
0
0
105
774
1.38
2.51
4.4
5.6
1.57
1.58
%
0.03
97
735
7
16
4.39
2.47
1.0
1.1
—
—
—
0
0
6
13
4.63
2.27
1.2
1.1
—
—
—
0
0
42
652
0.64
2.25
3.0
3.4
4392.48
6342.16
u/ml
0.13
36
562
105
791
1.35
2.22
4.0
3.4
25.88
25.19
mmol/l
0.96
98
762
5
9
5.57
2.21
1.4
1.6
—
—
—
0
0
268
2269
1.22
2.21
6.0
6.3
1.04
1.05
mmol/l
0.20
252
2099
151
1202
1.28
2.16
1.7
1.7
—
—
—
0
0
30
174
1.74
2.14
1.3
1.4
—
—
—
0
0
121
1544
0.77
2.12
1.4
1.4
—
—
—
0
0
15
68
2.22
2.11
1.6
1.4
—
—
—
0
0
63
442
1.44
2.04
1.5
1.6
0.27
16.54
iu/ml
0.49
15
73
21
111
1.90
2.01
1.3
1.5
1.51
1.04
promille
0.53
16
88
1227
12757
0.86
2.00
5.2
5.3
1.89
1.98
mu/l
1.68
1144
11677
7
21
3.34
1.96
1.3
1.3
—
—
—
0
0
142
1748
0.80
1.88
3.3
4.3
10.79
19.36
ug/l
0.62
115
1450
161
1953
0.81
1.86
1.3
1.4
—
—
—
0
0
899
8453
1.14
1.86
7.9
10.1
4.20
4.21
e9/l
0.04
780
7326
144
1168
1.25
1.80
1.4
1.5
—
—
—
0
0
13
62
2.11
1.65
1.2
1.1
1704.54
1597.87
miu/ml
0.08
13
62
172
1438
1.22
1.65
2.0
2.2
384.49
375.90
nmol/l
0.25
154
1342
20
112
1.80
1.64
1.8
2.4
8.48
8.03
mmol/l
0.14
20
112
30
189
1.60
1.63
1.4
1.8
—
—
—
0
0
10
42
2.39
1.61
1.1
1.1
—
—
—
0
0
111
1378
0.79
1.60
2.1
2.4
13.72
13.27
nmol/l
0.21
96
1234
720
7687
0.89
1.60
2.7
2.7
—
—
—
0
0
29
183
1.59
1.57
1.6
1.5
273.86
277.73
mosm/kgh2o
0.31
22
135
360
4011
0.87
1.57
3.4
3.2
0.17
0.02
0.40
12
103
581
5362
1.13
1.56
2.7
3.5
2.37
2.35
mmol/l
1.55
516
4827
6
21
2.86
1.50
1.2
1.2
—
—
—
0
0
6
21
2.86
1.50
1.8
1.8
—
—
—
0
0
617
6628
0.89
1.50
3.1
3.1
158.73
144.12
ug/l
0.38
564
6121
64
845
0.75
1.50
1.7
1.8
—
—
—
0
0
0
45
0.00
1.50
0.0
1.2
—
—
—
0
0
7
28
2.51
1.45
1.1
1.2
1.19
1.18
mmol/l
—
7
28
7
152
0.46
1.43
1.1
1.5
—
—
—
0
0
58
431
1.36
1.43
1.4
1.3
—
—
—
0
0
16
88
1.83
1.41
1.3
1.2
—
—
—
0
0
16
88
1.83
1.41
1.3
1.2
—
—
—
0
0
29
189
1.54
1.40
1.3
1.6
19.97
30.36
ng/l
0.90
29
189
14
248
0.56
1.36
1.2
1.1
—
2.31
—
0
7
5
18
2.78
1.28
1.0
1.1
—
—
—
0
0
226
1987
1.16
1.26
3.0
4.3
225.46
247.12
u/l
2.07
216
1886
724
7654
0.91
1.24
4.6
4.0
0.00
0.00
estimate
-0.00
158
1638
74
586
1.27
1.20
2.5
1.7
0.42
0.33
mg/l
0.45
33
273
30
205
1.47
1.20
1.1
1.1
—
23.33
—
0
6
526
4891
1.11
1.20
3.7
3.4
33.98
37.97
u/l
0.49
505
4622
26
173
1.51
1.18
1.5
1.9
—
—
—
0
0
14
79
1.78
1.17
2.4
3.9
—
—
—
0
0
75
933
0.79
1.16
1.8
1.9
—
—
—
0
0
0
35
0.00
1.15
0.0
1.3
—
—
—
0
0
737
7761
0.91
1.14
4.7
4.1
0.00
2.95
estimate
1.07
158
1669
16
95
1.69
1.14
1.5
2.0
—
—
—
0
0
47
355
1.33
1.09
1.3
1.4
—
—
—
0
0
47
355
1.33
1.09
1.3
1.4
—
—
—
0
0
30
418
0.71
1.05
2.2
1.6
13608.64
16377.06
e6/l
0.14
22
296
9
46
1.96
1.03
1.2
1.6
2.00
4.17
umol/l
—
9
39
5
22
2.28
1.03
1.4
1.2
—
—
—
0
0
26
370
0.70
1.03
1.3
1.6
—
—
—
0
0
744
7801
0.92
1.01
4.7
4.1
0.03
0.21
estimate
0.44
150
1556
31
222
1.40
1.01
4.9
5.6
368.86
353.50
umol/l
0.21
25
202
127
1475
0.85
1.00
3.2
2.5
32.46
71.86
u/l
0.63
106
1233
11
61
1.81
0.98
1.0
1.1
—
—
—
0
0
0
31
0.00
0.96
0.0
8.7
—
10.36
—
0
31
33
444
0.74
0.95
1.5
1.8
7.15
3.90
mg/l
0.46
23
341
304
2780
1.11
0.95
1.4
1.5
2.38
2.58
g/l
0.93
191
1662
999
9647
1.09
0.94
5.9
5.0
2899.06
1631.23
e6/l
0.27
18
151
7
37
1.90
0.94
1.1
1.1
—
—
—
0
0
19
125
1.53
0.94
2.3
2.3
568.43
657.68
ml
0.51
14
81
8
143
0.56
0.93
1.1
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
47
599
0.78
0.93
2.9
3.5
0.35
0.36
iu/ml
0.03
24
338
9
52
1.73
0.92
5.1
2.8
5.49
4.86
kpa
—
9
52
9
52
1.73
0.92
5.1
2.8
8.66
10.20
kpa
—
9
52
177
1569
1.14
0.92
1.9
1.8
1.71
1.53
%
1.18
158
1340
26
359
0.72
0.89
1.3
1.2
—
—
—
0
0
6
29
2.07
0.89
1.2
1.1
—
—
—
0
0
47
595
0.78
0.89
1.4
1.3
—
—
—
0
0
21
300
0.70
0.88
1.1
1.3
276.56
212.29
miu/ml
—
9
125
23
161
1.43
0.86
3.1
2.6
—
—
—
0
0
34
256
1.33
0.85
1.8
1.8
4.89
4.70
mmol/24h
0.11
28
227
13
80
1.63
0.84
1.2
1.9
—
—
—
0
0
13
80
1.63
0.84
1.2
1.9
—
—
—
0
0
13
80
1.63
0.84
1.2
1.9
—
—
—
0
0
13
80
1.63
0.84
1.2
1.9
—
—
—
0
0
487
5158
0.92
0.81
2.9
3.3
1347.69
1544.85
ng/l
0.36
408
4461
13
81
1.61
0.81
2.0
2.4
—
—
—
0
0
8
47
1.71
0.80
1.3
1.9
—
—
—
0
0
28
373
0.75
0.79
2.6
3.4
398.33
1061.17
u/ml
0.42
28
353
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
1.99
—
0
12
10
59
1.70
0.76
1.1
1.1
—
—
—
0
0
45
360
1.26
0.75
1.2
1.3
—
—
—
0
0
17
116
1.47
0.74
1.1
1.1
103.12
104.47
pmol/l
0.05
17
116
73
616
1.19
0.74
3.1
3.8
34.18
66.21
mg/l
0.99
61
529
143
1273
1.13
0.73
3.0
4.0
1.22
1.22
mmol/l
0.40
116
1098
161
1790
0.89
0.73
3.3
3.2
7.74
8.17
umol/l
0.12
138
1612
6
106
0.56
0.72
1.2
1.4
—
63.64
—
0
11
183
1660
1.11
0.70
4.2
3.6
—
—
—
0
0
19
262
0.72
0.69
5.6
4.1
2.84
1.47
%
0.52
19
244
25
187
1.34
0.68
1.6
1.4
—
—
—
0
0
5
91
0.55
0.67
1.8
1.8
—
—
—
0
0
5
92
0.54
0.67
1.6
3.6
4.00
20.54
umol/l
—
5
67
152
1371
1.12
0.65
3.2
2.5
1.41
0.46
e6/l
0.47
146
1311
72
616
1.18
0.65
3.1
3.8
44.69
58.82
mg/l
0.66
61
528
25
189
1.33
0.64
1.6
1.4
—
—
—
0
0
25
189
1.33
0.64
1.6
1.4
—
—
—
0
0
30
381
0.78
0.63
4.0
3.5
0.84
0.82
nmol/l
0.11
25
312
382
4042
0.93
0.62
3.9
3.6
0.02
0.04
estimate
0.52
127
1282
20
147
1.36
0.61
1.2
1.6
—
—
—
0
0
20
147
1.36
0.61
1.2
1.6
—
—
—
0
0
20
147
1.36
0.61
1.2
1.6
—
—
—
0
0
77
887
0.86
0.61
1.2
1.3
376.87
220.97
u/ml
0.68
70
812
33
406
0.81
0.55
2.2
2.1
—
—
—
0
0
155
1694
0.91
0.55
2.4
2.4
140.01
134.61
ug/g
0.09
113
1360
342
3236
1.07
0.53
2.7
3.1
2.46
2.46
mmol/l
0.41
302
2890
148
1353
1.10
0.52
2.6
3.4
161.32
226.42
ng/l
1.25
142
1257
23
179
1.29
0.51
1.7
1.4
—
—
—
0
0
23
179
1.29
0.51
1.7
1.4
—
—
—
0
0
829
8066
1.05
0.51
6.1
6.9
11.56
12.15
umol/l
0.53
794
7706
23
180
1.28
0.49
1.7
1.4
—
—
—
0
0
464
4832
0.95
0.47
3.1
2.7
53.74
77.99
u/l
0.84
435
4475
5
81
0.62
0.46
6.2
3.5
2.00
0.98
%
—
5
81
37
439
0.84
0.45
1.7
1.4
—
—
—
0
0
558
5773
0.95
0.44
5.0
4.3
160.86
108.61
e6/l
0.45
421
4197
237
2513
0.93
0.43
1.3
1.3
30.93
32.15
iu/ml
0.05
57
788
187
1747
1.08
0.43
8.5
7.7
—
—
—
0
0
11
78
1.41
0.43
1.3
1.4
—
—
—
0
0
8
56
1.43
0.42
3.5
2.7
0.61
0.60
mmol/l
—
8
56
28
337
0.83
0.41
1.5
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
0.03
—
0
8
83
748
1.12
0.41
2.2
2.0
0.53
1.94
ug/l
2.62
74
667
361
3769
0.95
0.41
2.4
2.6
—
—
—
0
0
0
17
0.00
0.40
0.0
1.0
—
—
—
0
0
5
34
1.47
0.40
1.4
1.4
—
—
—
0
0
8
60
1.33
0.40
1.6
1.1
98.38
176.16
iu/ml
—
8
60
680
6617
1.05
0.40
2.6
2.5
77.98
77.78
nmol/l
0.06
606
5908
171
1828
0.93
0.40
4.4
5.2
32.04
32.58
%
0.28
113
1183
25
303
0.82
0.40
1.5
1.4
—
20.93
—
0
5
7
104
0.67
0.39
1.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
13
98
1.33
0.37
1.2
1.2
—
—
—
0
0
27
225
1.20
0.37
1.6
1.5
—
—
—
0
0
8
115
0.69
0.37
1.4
1.5
—
—
—
0
0
12
90
1.34
0.35
1.2
1.2
—
—
—
0
0
71
785
0.90
0.35
3.8
3.7
1.02
1.02
ratio
0.15
66
725
559
5752
0.96
0.35
4.7
4.0
0.03
0.02
estimate
0.07
136
1363
357
3432
1.05
0.35
4.8
4.2
1.02
1.02
kg/l
0.15
248
2324
22
266
0.82
0.35
3.1
3.7
—
425.07
—
0
27
23
275
0.83
0.33
1.7
1.5
—
—
—
0
0
402
3883
1.05
0.33
5.0
4.5
88.01
86.40
%
0.75
394
3805
29
338
0.86
0.32
2.0
2.0
—
—
—
0
0
76
831
0.91
0.32
1.7
1.8
1.54
1.52
g/l
0.06
69
730
14
176
0.79
0.32
1.2
1.1
1.03
2.16
u/ml
—
7
94
7
97
0.72
0.31
1.1
1.2
9.53
9.28
mmol/l
—
7
92
29
249
1.17
0.30
1.3
1.3
—
—
—
0
0
16
129
1.24
0.30
1.1
1.1
—
—
—
0
0
8
109
0.73
0.29
1.4
2.6
12.50
19.16
nmol/l
—
8
99
8
110
0.73
0.29
2.1
1.6
—
—
—
0
0
29
334
0.87
0.29
1.7
1.5
—
—
—
0
0
19
227
0.84
0.28
1.1
1.1
1.59
1.52
g/l
0.49
19
207
447
4346
1.04
0.28
4.9
4.1
0.00
0.00
estimate
0.96
142
1492
1080
10664
1.04
0.27
4.7
4.5
12.43
13.11
mm/h
0.78
1017
9909
8
63
1.27
0.27
1.1
2.0
—
—
—
0
0
8
63
1.27
0.27
1.1
2.0
—
—
—
0
0
12
150
0.80
0.27
1.8
1.6
—
—
—
0
0
5
71
0.70
0.26
1.4
1.2
—
—
—
0
0
5
71
0.70
0.26
1.4
1.2
122.74
415.73
u/l
—
5
63
23
266
0.86
0.25
1.5
1.5
144.33
143.05
au/ml
—
9
82
68
628
1.09
0.24
2.5
2.8
—
—
—
0
0
17
142
1.20
0.24
5.5
1.8
2.19
4.68
mg/l
5.86
17
137
93
871
1.07
0.24
1.6
1.5
—
—
—
0
0
60
554
1.09
0.22
2.9
3.7
1.67
3.60
ratio
1.16
32
330
7
93
0.75
0.22
1.4
1.9
59.26
114.90
ng/l
—
7
93
5
40
1.25
0.22
1.4
3.1
4.20
5.47
ug/l
—
5
40
33
368
0.89
0.22
1.4
1.5
—
—
—
0
0
12
146
0.82
0.22
1.2
1.1
95.83
95.85
%
0.00
12
137
40
440
0.91
0.21
3.7
3.3
3.25
3.56
g/l
0.65
40
419
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
4.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
29.23
—
0
11
51
469
1.09
0.21
1.5
1.6
16.24
17.84
u/ml
—
7
94
0
13
0.00
0.21
0.0
1.5
—
16.63
—
0
8
17
145
1.17
0.20
1.3
1.3
—
—
—
0
0
10
123
0.81
0.20
1.4
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
42
459
0.91
0.20
2.1
3.5
94.74
90.69
%
0.43
42
446
22
250
0.88
0.20
1.5
1.7
—
—
—
0
0
38
417
0.91
0.20
1.4
1.4
42.01
27.41
iu/l
1.23
33
342
37
406
0.91
0.19
1.5
1.2
—
—
—
0
0
30
332
0.90
0.18
1.5
1.5
—
—
—
0
0
116
1214
0.95
0.18
4.3
2.9
75.10
63.13
ml/min/173m2
0.49
51
530
54
503
1.08
0.18
7.0
5.0
1.60
1.64
mg/l
0.11
54
454
131
1256
1.05
0.17
4.7
4.2
90.07
95.75
ng/l
0.30
118
1088
18
157
1.15
0.17
1.3
1.2
1.26
1.45
nmol/l
0.37
13
140
37
403
0.92
0.17
1.5
1.2
—
—
—
0
0
905
9143
0.98
0.16
3.9
3.5
45.65
54.25
u/l
1.58
851
8530
23
256
0.90
0.16
1.4
1.5
117.04
295.48
pmol/l
1.22
23
251
30
328
0.91
0.15
1.9
1.9
5.55
21.83
iu/l
0.45
13
132
49
458
1.07
0.15
1.4
1.7
—
—
—
0
0
257
2628
0.97
0.13
3.9
3.4
2.70
1.94
e6/l
0.44
148
1354
37
344
1.08
0.13
1.3
1.4
10.89
8.69
u/l
0.47
29
265
35
376
0.93
0.13
2.8
2.4
89.94
103.01
ug/min
0.07
18
226
25
273
0.91
0.13
1.5
1.4
—
—
—
0
0
682
6894
0.98
0.13
2.6
2.9
—
—
estimate
—
0
0
261
2555
1.03
0.13
2.5
2.3
29.58
29.81
s
0.32
253
2478
21
231
0.91
0.12
1.0
1.1
—
—
—
0
0
1056
10630
0.98
0.12
4.1
4.2
15.19
14.93
pmol/l
2.66
980
9654
15
133
1.13
0.12
1.3
1.4
11.47
13.66
u/l
0.91
15
126
21
191
1.10
0.11
1.1
1.1
—
—
—
0
0
41
435
0.94
0.11
1.3
1.7
—
—
—
0
0
19
208
0.91
0.10
1.2
1.4
15013.57
105872.36
e6/l
1.72
14
117
284
2793
1.02
0.10
2.6
2.7
13.21
12.52
umol/l
0.77
257
2607
81
782
1.04
0.09
2.4
3.5
4.36
4.46
pmol/l
0.39
73
689
59
615
0.96
0.09
1.1
1.1
—
—
—
0
0
524
5187
1.01
0.09
4.3
3.6
42.06
92.18
e6/l
1.95
414
4040
369
3643
1.02
0.09
3.3
2.8
5.84
5.21
e6/l
0.34
340
3333
157
1605
0.98
0.09
8.6
7.4
9.51
10.54
mmol/l
1.02
151
1541
30
318
0.94
0.08
5.6
3.7
22.07
28.16
mg/l
0.78
23
225
21
226
0.93
0.08
1.2
1.1
5.61
1.84
u/ml
0.38
13
136
7
64
1.09
0.08
1.1
2.0
—
—
—
0
0
43
449
0.96
0.07
1.6
1.7
—
—
—
0
0
11
122
0.90
0.07
1.8
1.5
—
—
—
0
0
9
87
1.03
0.07
1.3
1.6
—
—
—
0
0
9
105
0.86
0.06
2.0
1.6
—
—
—
0
0
20
188
1.06
0.05
1.1
1.0
—
—
—
0
0
241
2436
0.99
0.05
2.6
2.7
23.75
22.35
%
0.86
221
2277
146
1439
1.02
0.05
2.6
2.4
7.21
7.06
ug/l
0.02
131
1267
162
1600
1.01
0.04
2.5
2.8
65.86
69.27
e9/l
0.83
123
1187
450
4473
1.01
0.04
4.1
3.5
0.53
0.46
e6/l
0.29
348
3354
317
3146
1.01
0.04
3.9
4.2
395.62
417.98
ng/l
0.03
263
2601
319
3213
0.99
0.04
1.8
1.8
1.27
1.37
mg/l
0.22
249
2519
29
279
1.04
0.04
1.2
1.4
254.44
274.98
u/ml
0.24
16
147
21
200
1.05
0.03
1.2
1.2
1.89
5.55
u/ml
—
9
91
47
482
0.97
0.03
1.4
1.5
257.16
272.67
ug/g
0.27
32
297
14
149
0.94
0.03
1.4
1.3
—
—
—
0
0
16
151
1.06
0.03
2.4
3.7
12.75
11.53
index
—
8
90
420
4220
0.99
0.03
2.3
2.4
2.89
2.89
mg/l
0.01
355
3622
33
320
1.03
0.03
1.5
1.8
—
—
—
0
0
21
201
1.05
0.03
1.9
2.4
30.30
22.56
mg/l
—
10
76
44
430
1.02
0.02
1.5
1.6
—
—
—
0
0
18
188
0.96
0.02
3.0
4.2
—
—
—
0
0
260
2614
0.99
0.02
2.5
2.7
2.26
2.27
g/l
0.14
233
2420
19
198
0.96
0.02
1.2
1.4
0.67
9.69
nmol/l
0.50
19
188
284
2826
1.01
0.02
3.6
3.2
0.97
1.07
e6/l
0.27
177
1558
1128
11296
1.00
0.02
8.3
8.6
77.10
81.21
u/l
2.48
1072
10704
29
298
0.97
0.02
1.2
1.3
—
143.96
—
0
5
16
153
1.05
0.01
1.0
1.1
1.00
2.63
eliau/ml
—
6
51
20
207
0.97
0.01
1.2
1.2
1.57
3.29
u/ml
—
7
76
39
383
1.02
0.01
1.5
1.5
—
—
—
0
0
10
94
1.06
0.01
1.4
1.5
128.14
160.42
pmol/l
—
10
94
605
6043
1.00
0.00
4.6
4.2
43.99
77.47
ng/l
1.20
504
4566
12
119
1.01
0.00
1.0
1.1
—
—
—
0
0
14
139
1.01
0.00
1.1
1.2
8.64
13.21
u/l
0.89
14
126
44
441
1.00
0.00
3.2
3.5
2.14
1.77
index
0.15
22
241
23
234
0.98
0.00
5.5
6.8
11.58
12.44
mg/l
0.43
23
219
40
404
0.99
0.00
1.6
1.3
—
—
—
0
0
47
472
1.00
0.00
1.5
1.7
—
—
—
0
0
11
112
0.98
0.00
1.0
1.1
—
—
—
0
0
11
112
0.98
0.00
1.0
1.1
—
—
—
0
0
11
107
1.03
0.00
1.0
1.1
—
—
—
0
0
11
107
1.03
0.00
1.0
1.1
—
—
—
0
0
23
233
0.99
0.00
1.5
1.7
—
—
—
0
0
79
795
0.99
0.00
1.1
1.2
130.93
145.95
u/ml
0.11
24
306
5
58
0.86
-0.00
1.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
2.40
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
66
0.91
-0.00
1.7
1.5
—
2024609.80
—
0
5
6
67
0.90
-0.00
1.0
1.2
—
—
—
0
0
5
52
0.96
-0.00
1.2
2.5
11.94
180.78
ug/l
—
5
43
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
38.90
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
13
130
1.00
-0.00
1.1
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
10.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1745.20
—
0
5
0
5
0.00
-0.00
0.0
7.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
10
100
1.00
-0.00
1.3
1.5
77.00
88.69
umol/l
—
10
100
9
97
0.93
-0.00
1.3
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.2
—
—
—
0
0
9
97
0.93
-0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
7.60
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
21.43
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint G6_NEUATR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_NEUATR | 7.442 [6.44, 8.6] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.176 |
During the follow-up period (1.1.1998 — 31.12.2019), 2750 out of 4587 females with G6_NEUATR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_NEUATR | 5.431 [4.76, 6.19] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 3012 out of 5076 males with G6_NEUATR died.
Mortality risk
Mortality risk for people of age
years, who have G6_NEUATR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.823% | 0.863% |
| 5 | 3.911% | 5.649% |
| 10 | 10.404% | 14.121% |
| 15 | 19.039% | 26.114% |
| 20 | 31.816% | 40.692% |
Relationships between endpoints
↥Index endpoint: G6_NEUATR – Systemic atrophies primarily affecting the central nervous system
GWS hits: 13
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data